| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Bone Biologics Corporation, a medical device enterprise, specializes in fostering bone regeneration for spinal fusion, leveraging its advanced recombinant human protein technology. Its flagship product, NELL-1/DBX, is a unique combination of an osteostimulative recombinant protein designed for precise, targeted control over bone regrowth. The company is currently advancing the NELL-1/DBX Fusion Device, intended for spinal fusion interventions in skeletally mature individuals experiencing single-level degenerative disc disease within the L4-S1 …
Over the last 12 months, insiders at Bone Biologics Corporation have bought $0 and sold $0 worth of Bone Biologics Corporation stock.
On average, over the past 5 years, insiders at Bone Biologics Corporation have bought $21,637 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 8,000 shares for transaction amount of $5,120 was made by Walsh Deina H (Chief Financial Officer) on 2023‑09‑13.
| 2023-09-13 | Walsh Deina H | Chief Financial Officer | 8,000 0.2552% | $0.64 | $5,120 | -55.66% | ||
| 2023-09-11 | Frelick Jeff | Chief Executive Officer | 9,500 0.311% | $0.69 | $6,530 | -55.50% | ||
| 2023-09-06 | Walsh Deina H | Chief Financial Officer | 7,000 0.219% | $0.71 | $4,967 | -58.20% | ||
| 2023-08-31 | Frelick Jeff | Chief Executive Officer | 7,600 0.2366% | $0.66 | $5,020 | -54.06% | ||
| 2020-01-02 | Hankey Don | Chairman of the Board | 195,000 1.6745% | $1.00 | $195,000 | |||
| 2020-01-02 | Hankey Bret | director | 195,000 1.6745% | $1.00 | $195,000 | |||
| 2019-08-06 | Hankey Don | Chairman of the Board | 553,191 – | $0 | $0 | |||
| 2019-08-06 | Hankey Bret | director | 553,191 – | $0 | $0 | |||
| 2019-07-15 | Hankey Don | Chairman of the Board | 85,106 – | $0 | $0 | |||
| 2019-07-15 | Hankey Bret | director | 85,106 – | $0 | $0 | |||
| 2019-06-20 | Hankey Bret | director | 1.06M – | $0 | $0 | |||
| 2019-06-20 | Hankey Don | Chairman of the Board | 1.06M – | $0 | $0 | |||
| 2019-05-07 | Hankey Don | Chairman of the Board | 1.06M – | $0 | $0 | |||
| 2019-05-07 | Hankey Bret | director | 1.06M – | $0 | $0 | |||
| 2019-03-25 | Hankey Don | Chairman of the Board | 1.49M – | $0 | $0 | |||
| 2019-03-25 | Hankey Bret | director | 1.49M – | $0 | $0 | |||
| 2018-12-17 | Hankey Don | Chairman of the Board | 18.01M – | $0 | $0 | |||
| 2018-12-17 | Hankey Bret | director | 18.01M – | $0 | $0 | |||
| 2016-02-29 | MUSCULOSKELETAL TRANSPLANT FOUNDATION, INC. | 10 percent owner | 731,707 23.9735% | $2.05 | $1.5M | |||
| 2015-12-22 | Sale | SOO B CHIA | director | 5,274 0.1332% | $1.58 | $8,333 |
| Hankey Don | Chairman of the Board | 28563398 842.8123% | $10.1M | 7 | 0 | |
| Hankey Bret | director | 28122518 829.8034% | $9.94M | 7 | 0 | |
| MUSCULOSKELETAL TRANSPLANT FOUNDATION, INC. | 10 percent owner | 11640096 343.4611% | $4.11M | 1 | 1 | |
| Frelick Jeff | Chief Executive Officer | 17204 0.5076% | $6,081.61 | 2 | 0 | <0.0001% |
| Walsh Deina H | Chief Financial Officer | 15000 0.4426% | $5,302.50 | 2 | 0 | <0.0001% |
| Increased Positions | 6 | +100% | 38,411 | +292.21% |
| Decreased Positions | 2 | -33.33% | 344 | -2.62% |
| New Positions | 3 | New | 22,065 | New |
| Sold Out Positions | 2 | Sold Out | 344 | Sold Out |
| Total Postitions | 10 | +66.67% | 51,212 | +289.59% |
| Drw Securities, Llc | $17.00 | 0.55% | 11,027 | +11,027 | New | 2025-09-30 |
| Tower Research Capital Llc (Trc) | $2.00 | 0.07% | 1,464 | +1,264 | +632% | 2025-09-30 |
| Sbi Securities Co., Ltd. | $0 | 0.01% | 230 | +230 | New | 2025-09-30 |
| Citigroup Inc | $0 | 0.01% | 206 | +206 | New | 2025-09-30 |
| Clear Street Llc | $0 | 0.01% | 138 | +138 | New | 2025-06-30 |
| Clear Street Group Inc. | $0 | 0.01% | 138 | +138 | New | 2025-09-30 |
| Ubs Group Ag | $0 | <0.01% | 66 | -47 | -41.59% | 2025-09-30 |
| Bank Of America Corp /De/ | $0 | <0.01% | 14 | +10 | +250% | 2025-09-30 |